Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 14–Jun 21, 2026)

· 1 min read

One FDA decision date falls in this week: ACHV’s NDA for nicotine dependence, with a June 20 target date. On the Run-up Radar, UNCY’s NDA decision is 15 days out, and IBRX and AXSM have trial milestones in 17 days. TNGX was last week’s biggest biotech gainer, up 53%.

💊 FDA Decisions (PDUFA Dates)

Date Ticker Drug Indication Type
2026-06-20 ACHV — nicotine dependence NDA

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • UNCY: NDA in 15 days, score 72/100
  • IBRX: Phase 2, Recruiting in 17 days, score 55/100
  • AXSM: Phase 2, Recruiting in 17 days, score 53/100

📈 Last Week’s Biggest Gainers

  • TNGX +52.97% (volume 6.5x average)
  • NUVL +39.28% (volume 77.0x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.